James Quigley
Stock Analyst at Morgan Stanley
(1.31)
# 3,653
Out of 5,147 analysts
25
Total ratings
50%
Success rate
-0.36%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $73 → $127 | $91.35 | +39.03% | 7 | Dec 9, 2025 | |
| NVO Novo Nordisk | Maintains: Buy | $60 → $54 | $37.45 | +44.19% | 1 | Nov 28, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $168.62 | -30.02% | 2 | Sep 12, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $48.66 | +33.58% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $9.10 | +15.38% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $33.66 | +18.84% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.40 | +370.59% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $73 → $127
Current: $91.35
Upside: +39.03%
Novo Nordisk
Nov 28, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $37.45
Upside: +44.19%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $168.62
Upside: -30.02%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $48.66
Upside: +33.58%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $9.10
Upside: +15.38%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $33.66
Upside: +18.84%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.40
Upside: +370.59%